ASSESSMENT OF PROFESSIONAL’S ADHERENCE TO JOINT NATIONAL COMMITTEE 8 GUIDELINES IN THE MANAGEMENT OF HYPERTENSION by D’SOUZA, SCHNELL JENNIFER et al.
Vol 12, Issue 1, 2019
Online - 2455-3891 
Print - 0974-2441
ASSESSMENT OF PROFESSIONAL’S ADHERENCE TO JOINT NATIONAL COMMITTEE 8 
GUIDELINES IN THE MANAGEMENT OF HYPERTENSION
SCHNELL JENNIFER D’SOUZA1, ANCEL NEETHU MANI1, NIMISHA KURIAN1, JAIKANTH C2*
1Department of Pharmacy Practice, Karavali College of Pharmacy, Mangalore, Karnataka, India. 2Department of Pharmacology, Karavali 
College of Pharmacy, Mangalore, Karnataka, India. Email: jaikanthjai@gmail.com
Received: 14 July 2018, Revised and Accepted: 31 August 2018
ABSTRACT
Objectives: Hypertension is the most insidious ailment in primary care with its management being a daily affair. The avail of antihypertensive 
medications has affirmed their efficacy in blood pressure alleviation. Yet, the methodical choice of medication with which treatment ought to commence 
at the precise blood pressure threshold and maintained at a target level was undiscerned. Consequently, the Eighth Joint National Committee grants an 
evidence-based tool, which was employed in the appraisal of professional’s adherence to joint national committee 8 guidelines.
Methods: A prospective, observational study was governed. Aggregate patients with hypertension with/without diabetes mellitus (DM) and/
or chronic kidney failure admitted in general medicine and the dialysis unit of the tertiary health care hospital, for 4 months were enrolled. The 
rationality of antihypertensive medications and target blood pressure was noted.
Results: Patients matriculated to 125, 90 males and 35 females. Average age perceived was between 51 and 60 years, with the length of stay 
14.39 (standard deviation [SD]±1.52) and 9.3 (SD±0.46) days in the respective unit. The gross medication endorsed represents 1085 medications, 
incorporating 337 antihypertensive medications. The optimal choice of an antihypertensive medicine was clonidine and amlodipine. Adherence in the 
populace with lone hypertension was cent percent, trailed by hypertension with DM 82.35% and minimal in hypertension with chronic kidney disease.
Conclusion: 86-medication compiled adherence to the guidelines (25.52%). Rationality of medication depicts 25.6% were rational and 73.6% 
distinguish as non-rational, amid a demise of a sole victim. A significant high-grade defiance of health-care practitioners to the Eighth Joint National 
Committee guidelines was evidenced from our study.
Keywords: Joint national committee 8, Adherence, Hypertension, Medication regimen.
INTRODUCTION
Hypertension asserted by the World Health Organization as high or 
elevated blood pressure. An infirmity in which the blood vessels has 
persistently escalate pressure, fostering the heart to pump harder [1]. 
It is the most insidious ailment in primary care with its management 
being a daily affair [2]. Clinching an asymptomatic complexion 
has secured it as an alias of “the silent killer” [3]. The expectancy of 
encountering hypertension is gauged at 90% [4], with it affecting nearly 
26% of adult population currently and projected to affect 1.56 billion 
(29%) of the world’s adult population by 2025. Its pervasiveness in 
India is 66 million with 34 million in urban and 32 million in rural 
areas [5]. India is cruising through a demographic metamorphosis as 
a developing country with an amplification in population trends. This 
momentous proliferation of life can genesis non-communicable disease 
toward eclipsing infectious disease that implicates a stain on the health 
finances of the country [6].
Hypertension and diabetes mellitus (DM) are overt to coexist in 
various populations [7]. In accordance with the WHO, DM incidence 
in adults worldwide was accounted for 4.0% in 1995. It is predicted 
to levitate to 5.4% by the year 2025. The adulated populace would 
mount from 135 million in 1995 to 300 million in the year 2025. The 
peril of cardiovascular disease amplified by an aspect of two to three 
in DM populace with every level of systolic pressure [8]. In inhabitants 
of DM in tandem with hypertension, an attenuation in blood pressure 
poses an early benefit in results and enhanced cost-effectiveness, then 
maintaining a taut control over blood glucose levels [9]. DM is cardinal 
in conjunction with hypertension designated the secondary source, 
yet an autonomous menace in end-stage renal disease (ESRD). The 
sequentially chronic renal disease can instigate or be a consequence of 
hypertension [10]. Predominantly, renal disease populace is inflicted 
with hypertension as well, thus navigating to the deterioration of kidney 
function. Hence, the preventive stratagem in ESRD ought to comprise 
the prevention, treatment, and control of blood pressure [11].
Up until 1950, there was no effectual treatment available in 
the management of hypertension. With the development of 
antihypertensive and their efficacy in plummeting blood pressure in 
the past 3 decades has tinted it as a therapeutic coup [12]. Conversely, 
the proficient choice of an antihypertensive medication with which 
treatment ought to be instigated, at precise blood pressure threshold 
and sustain at target level was unresolved [13]. Therefore, the Eighth 
Joint National Committee on the prevention, detection, evaluation, and 
treatment of elevated blood pressure endows an evidence-based tool 
for a physician in the clinical advance of hypertension management [14]. 
The Joint National Committee is punctilious as the “golden standard” 
hypertension management [15]. The 2014 Joint National Committee-8 
(JNC-8) guidelines encompass rigorous scientific evidence and nine 
recommendations comprised by reviewing studies of hypertensive 
natives aged eighteen and elder [16]. They urge the use of four types of 
medication - calcium channel blockers (CCBs), angiotensin-converting 
enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), 
and diuretics on mainstay of randomized control trial evidence, with 
explicit recommendations according to race, chronic kidney disease 
(CKD), or diabetic status [17].
The current study aims to analyze the comorbidities in the 
populace deliberated, assess the physicians prescribing pattern of 
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antihypertensive medications, its rationality, and adherence to JNC-8 
guidelines. Rational prescription pattern utilizes the least number of 
medicaments to obtain the best possible therapeutic outcome in the 
shortest time duration. The management of hypertension requires both 
pharmacological and non-pharmacological methods [18]. Therefore, 
compliance with such guideline grants stanchion, due to an optimal 
management of an independent citizen’s treatment regimen.
MATERIALS AND METHODS
A prospective observational study was undertaken in the general 
Medicine and Dialysis Department of Father Muller Medical College 
Hospital, Mangalore, India. For a duration of 4 months, from November 
2016 to February 2017, after the authorization of the institutional ethics 
committee (FMMC/FMIEC/3054/2016). A sum of 125 individuals 
was integrated into the study. All hypertension populaces of age 18–
60 years admitted to the inpatient general medicine and dialysis in 
and outpatient ward, including folks with comorbidities of DM and/or 
CKD were incorporated. While patients with incomplete data or those 
reassigned to other departments in the span of 24 hours were excluded. 
The inhabitant’s information was compiled and documented in the data 
collection form generated. Medication adherence and rationality were 
assessed by weighing it against the treatment algorithm calibrated by 
the Eighth Joint National Committee of hypertension management. 
Medication units consumed were appraised by computing its daily 
define dose.
Statistical analysis
Statistical software SPSS (version 20) was employed for data analysis. 
Descriptive statistics such as percentages were reckoned for categorical 
variables. The mean and the standard deviation were employed to 
estimate continuous variables. Graphic representations were performed 
using Microsoft Excel 2007 for visual interpretation of analyzing data.
RESULTS
A total of 125 prescriptions were analyzed, 69 received from general 
medicine and 56 from dialysis ward. The study constituted of 90 (72%) 
males and 35 (28%) females populace. The age allocation was foremost 
seen amid 51–60 years (44%) and minimal in 18–28 years (5.6%), 
retaining a mean of 31.3 (standard deviation [SD]±23.8). The average 
length of stay was 14.39 (SD±1.52) and 9.3 (SD±0.46) days in the 
respective wards.
On appraising the aggregate of medication prescribed, 1085 medicines 
were achieved. The recurrent integer of medication consumed per 
individual was estimated at 6–10 (37.7%) with a bare minimum 
of 1–5 (29%) medications, preserving a mean of 14.9 (SD±1.5). 
Correspondingly, the antihypertensive medications cumulated to 337, 
with peak quantity consumed 3–4 (45.6%), shadowed by 1–2 (44.8%), 
and ≥5 (9.6%), with mean 41.7 (SD±25.7) (Table 1).
The survey of 125 populaces acquired 7 (5.6%) lone hypertension 
individuals, in conjugation with 17 (13.6%) inhabitants possessing DM, 
65 (52%) people with chronic kidney failure, and 36 (28.8%) patients 
have both of them as comorbidity (Fig. 1).
The overview of this study furnishes amlodipine as the most substantial 
prescribed antihypertensive medication with 1.95 units utilized. 
The predominant therapy spotted was triple combination therapy 
35 (28%), succeeded by monotherapy 31 (24.8%), double combination 
therapy 31 (24.8%), and trailed by multiple combination therapy 
28 (22.4%) (Table 2).
When contemplating the class of medication prescribed in 
hypertension and its comorbidities, the predominant choice of 
medication was CCBs, pursued by ARBs in hypertension lone 
patients, similarly, β blockers in populaces with DM, α2 agonist in 
individuals with CKD as comorbidity, and ARBs in inhabitants with 
both as comorbidity as shown in Fig. 2. The corresponding  unit of 
Table 1: Demographic data and patient details





























Length of stay in dialysis department
Twice in a week 39 (69.6)
Thrice in a week 17 (30.4)
Mean±SD 9.3±0.5
SD: Standard deviation
Table 2: Prescribing pattern of antihypertensive medications
Treatment Number of prescriptions (%)
Monotherapy 31 (24.8)
CCBs 18 (58.06)
Double combination therapy 31 (24.8)
CCBs+α2 agonist 7 (22.58)
Triple combination therapy 35 (28)
CCB+α2 agonist+diuretics/β blocker 5 (14.28)
Multiple therapy 28 (22.4)
CCBs+CCBs+β blockers+α2 agonist 6 (21.43)
CCBs: Calcium channel blockers
Fig. 1: Disease distribution
antihypertensive medication consumed by total populace is depicted 
in Table 3.
The adherence attained in the populace with hypertension lone was 
cent percent. Minimal adherence was ascertained in hypertension with 
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DM and CKD 19 (7.7%). Adherence of antihypertensive medication was 
86 (25.52%). The investigation of populace blood pressure on admission 
to the hospital confers 11 inhabitants with normal blood pressure, in 
collaboration with 20 prehypertension, 36 Stage I hypertension, and 
58 Stage II hypertension. The demise of a sole victim was witnessed. 
The rationality of antihypertensive medications portrayed, 32 (25.6%) 
rational while 92 (73.6%) were non-rational (Table 4).
DISCUSSION
Hypertension represents a predominant medical condition worldwide, 
a principal cause of stroke and a primary menace for coronary 
artery disease and its complications. The vital goal of treating it is 
to preclude and dwindle the prospect of hypertension-associated 
morbidity and mortality. The Eighth Report of the Joint National 
Committee on the prevention, detection, evaluation, and treatment of 
high blood pressure bequeaths a prominent evidence-based clinical 
guideline for the management of hypertension. The overview of this 
study depicts the incidence of hypertension was 90 (72%) males and 
35 (28%) female, which is parallel to the findings of Kothari N and 
Ganguly B, where primacy was top in male 474 (52.7%) than in female 
425 (47.3%) [14]. The age allocation in our survey was chiefly amid 
51–60 years (44%) and least in 18–28 (5.6%), this is contradictory to 
the analysis bared by Tadvi AY and Bandi JR, in which there were 73 
hypertensive participants, 12 (16.4%) in 20–25 years, 16 (21.9%) in 26–
30 years, 24 (32.9%) participants between 31 and 35, and 21 (28.8%) in 
the age group of 36–40 years [19]. The present study confers the sum of 
antihypertensive medications prescribed to be 337. The repeated count 
consumed by inhabitants was 3–4 (45.6%), trailed by 1–2 (44.8%), and 
≥5 (9.6%) medications. This is on par with that uncovered by Shah et al., 
in which a total of 63 antihypertensive medication were prescribed 
for 50 patients, where 38 (76%) received one medication followed by 
11 (22%) who received two and 1 patient (2%) who received three 
medications of different antihypertensive class, respectively [20]. 
Of the 125 populaces appraised, 7 (24.6%) were lone hypertensive, 
17 (13%) had DM, and 65 (10.1%) had chronic kidney failure as 
comorbidity, whereas 36 (28.8%) had both of them as comorbidities. 
This challenge, the investigation was done by Mohan, was among 
the 325 patients, 71.42% had DM with hypertension, and 28.57% 
had respiratory disorders with hypertension [21]. The predominant 
therapy was triple combination 35 (28%), succeeded by monotherapy 
31 (24.8%), double 31 (24.8%), and trailed by multiple combination 
therapy 28 (22.4%) which was paradoxical to the examination 
undertaken by Kothari N and Ganguly B that showed 45.60% of patients 
were stabilized on monotherapy, whereas 54.4% of patients were on 
multiple medication therapy [14]. The outcomes of this study exhibit, 
CCBs represent the prime choice of antihypertensive class, pursued by 
ARBs in hypertensive lone patients, similarly, β-blockers in populaces 
with DM, α2 agonist in individuals with CKD as comorbidity, and ARBs 
in inhabitants with both as comorbidities. When comprehending 
the substantial antihypertensive medication prescribed, amlodipine 
attained that spot with 1.95 units being consumed, an analysis 
conducted by Sweileh et al. gainsaid these findings by stating that 
ACE-I was the most common medication class both in mono and 
combination therapy [22]. The conclusion met in our study portrays, 
adherence attained in the populace with hypertension lone was cent 
percent. Minimal was ascertained in hypertension with DM and CKD 
19 (7.7%). The adherence of populaces in disease state corresponds 
an adherence of 86(25.52%) antihypertensive medications. This 
defies the finds of Kothari N and Ganguly B [14], in which 60% of 
antihypertensive prescribed in this group did not follow JNC-8 and the 
WHO guidelines. The recent study provides a limited external 
validity, as the sample obtained was not a representation of an entire 
population; it represents only the populace that was acquainted with 
the hospital where the investigation was executed. A certain amount 
of recall bias may be absorbed, as information concerning patient 
treatment was attained from medical records, thus posing a minimal 
limitation.
Table 3: Antihypertensive medication utilization
















Enalapril C09AA02 Oral 0.01 6 2.75 0.022
Ramipril C09AA05 Oral 0.0025 5 5 0.221
β-blockers Atenolol C07AB03 Oral 0.075 5 3.8 0.0032
Bisoprolol C07AB07 Oral 0.01 1 1 0.0082
Metoprolol C07AB02 Oral 0.15 7 25.32 0.0488
Propranolol C07AA05 Oral 0.16 1 0.125 0.00006
Timolol C07AA06 Oral 0.02 5 25 0.102
α2 agonist Clonidine C02AC01 Oral 0.00045 50 48555.3 1190.1
CCBs Amlodipine C08CA01 Oral 0.005 55 57 1.954
Cilnidipine C08CA14 Oral 0.01 49 68 0.9451
Nifedipine C08CA05 Oral 0.03 26 13.26 0.065
ARBs Telmisartan C09CA07 Oral 0.04 10 16 0.01949
Thiazide-type diuretics Furosemide C03CA01 Oral 0.04 5 8 0.01169
Parenteral 9 12 0.024
Torsemide C03CA04 Oral 0.015 22 39.36 1.0804
Metolazone C03BA08 Oral 0.005 1 1 0.016
α-blocker Prazosin C02CA01 Oral 0.005 6 6 0.654
α+β blocker Labetalol C07AG01 Oral 0.6 7 7.96 0.00073
Carvedilol C07AG02 Oral 0.0375 21 2.46 0.0226
Vasodilator Hydralazine C02DB01 Oral 0.1 15 2.5 0.0044
ATC: Anatomical therapeutic chemical, ARBs: Angiotensin receptor blockers, CCBs: Calcium channel blockers
Fig. 2: Antihypertensive medication class prescribed for 
hypertension with its comorbidities
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CONCLUSION
This prospective, observational study was embarked to investigate the 
prescribing patterns of antihypertensive medication, its adherence, 
and rationality with JNC 8 guidelines of hypertension management. The 
core findings propose that triple combination therapy was 
essentially prescribed, hypertension with CKD was the chiefly surveyed 
disease state. The predominant predilection for medication was CCBs. 
Rationality and adherence were revered at 25.6% and 25.5%. In this 
contemporary scenario, vaster populations of hypertensive individuals 
are afflicted with comorbidities. Contrarily, it is a sovereign peril for 
major disease conditions. Hence, the key to optimizing 
patients’ quality of life is preliminary blood pressure management. The 
lack of implementation of treatment algorithm has yielded a suboptimal 
adherence and rationality in the medication prescribed. Thus, education 
of professional’s about adherence to currently available and beneficial 
guidelines in patient’s therapy is crucial. Maintaining individual target 
blood pressure with a habitual checkup retaining a clinical pharmacist 
to provide knowledge about the imperatives of adherence to lifestyle 
modification and medication prescribed can be beneficial in treatment 
management.
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